Senores Pharmaceuticals Limited announced its un-audited financial results for the quarter and nine months ended December 31, 2025, on January 20, 2026. The Board of Directors approved the standalone and consolidated financial results.

The company reported a strong performance in Q3FY26, with consolidated total income reaching ₹174.56 Crores, a significant increase of 64% year-on-year. Profit After Tax (PAT) for the quarter stood at ₹33.58 Crores, marking an impressive growth of 105% compared to the same period last year.

For the nine months ended December 31, 2025, consolidated total income was ₹474.30 Crores, up 65% year-on-year. PAT for the nine-month period surged by 110% to ₹84.86 Crores.

The company highlighted robust growth in its Regulated Markets, with Q3FY26 revenue at ₹112.7 Crores (up 60.5% YoY) and EBITDA margin at 40%. For the nine months, revenue was ₹309.6 Crores (up 71.5% YoY) with an EBITDA margin of 40%.

In Emerging Markets, Q3FY26 revenue grew by 48% YoY to ₹38.4 Crores, with EBITDA margins improving significantly to 13% from 1% in Q3FY25. The company achieved its highest-ever quarterly revenue and EBITDA in Emerging Markets.

Senores Pharmaceuticals also provided an update on the acquisition of Apnar Pharmaceuticals, with Phase 1 (75% stake) completed and Phase 2 expected by Q2FY27. The company expects to launch three approved ANDAs from Apnar in Q4FY26.

The company's IPO proceeds utilization as of December 31, 2025, shows ₹362.12 Crores utilized out of ₹500 Crores, with ₹137.88 Crores unutilized. Major utilization was in funding inorganic growth and general corporate purposes.